Lonza forecasts 2026 sales growth of 11-12% for core CDMO business

Lonza AG

28/01/2026 05:46

Jan 28 - Lonza  LONN.S , the world's largest contract
drug manufacturer, on Wednesday set 2026 targets for its
contract development and manufacturing organization (CDMO)
business, expecting sales growth of 11% to 12% at constant
exchange rates and core profit margin expansion to above 32% of
sales.
     The Swiss company added it expected sales growth to be
higher in the first half of 2026 than in the second half.

(Reporting by Bernadette Hogg and Orest Dovhan in Gdansk,
editing by Milla Nissi-Prussak)
((bernadette.hogg@thomsonreuters.com))